The Galien Foundation has revealed its latest nominees for the 2021 Prix Galien USA Award highlighting innovations in biotechnology, pharmaceutical agents, medical technology and digital health products. Entrants to the competition must have received FDA approval within the past five years and demonstrate exceptional therapeutic potential. The Galien Foundation does not use financial data to…

Nexletol is similar to Nexlizet in its FDA indication as an adjunct to diet and statin therapy to treat adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who need additional help lowering of LDL cholesterol. In September, Nexletol began a direct-to-consumer campaign advertising the potential of the drug to support LDL cholesterol-lowering as an adjunct…

Nexlizet from Esperion is FDA-indicated for heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease. The indication is intended as an adjunct to diet and statin therapy for patients who need additional help reducing LDL cholesterol levels. The drug, which combines two cholesterol-reducing medicines (bempedoic acid and ezetimibe), won FDA approval early last year.